Eric Mou, MD, discusses efficacy data for tacabrutideg in chronic lymphocytic leukemia and what these findings may mean for the field.
Back
Investigating Tacbrutideg in CLL/SLL and Other B-Cell Malignancies
Irina Mocanu, MD, and colleagues outline data for the BTK degrader tacbrutideg in the BTK inhibitor–naive setting in CLL and other B-cell malignancies.
Investigating Tacbrutideg in CLL/SLL and Other B-Cell Malignancies
Episodes
All
All
Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Docirbrutinib Yields High Response Rates in MCL and CLL
4
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
5